Rhythm Pharmaceuticals, Inc. (RYTM) NASDAQ

Currency In USD

Key Executives

Name	Title	Pay	Year Born
David Meeker	Chairman, President & Chief Executive Officer	1.58M	1954
Joseph Shulman	Chief Technical Officer	734,854	1975
Alastair Garfield	Chief Scientific Officer	806,385	1980
Jennifer Lee	Executive Vice President & Head of North America	838,635	1975
Hunter C. Smith	Chief Financial Officer & Treasurer	892,477	1969
Yann Mazabraud	Executive Vice President & Head of International	972,148	1973
Pamela J. Cramer	Chief Human Resources Officer	0	1974
Sarah Ryan	Vice President of Sales & Marketing	0	N/A
Jim Flaherty	Senior Vice President & General Counsel	0	N/A
Elisabeth Cronert-Bendell	Senior Vice President & Head of Strategy	0	N/A
Christopher German	Corporate Controller & Principal Accounting Officer	0	1972
David Connolly	Head of Investor Relations & Corporate Communications	0	N/A

Name

Title

Pay

Year Born

David Meeker

Chairman, President & Chief Executive Officer

1.58M

1954

Joseph Shulman

Chief Technical Officer

734,854

1975

Alastair Garfield

Chief Scientific Officer

806,385

1980

Jennifer Lee

Executive Vice President & Head of North America

838,635

1975

Hunter C. Smith

Chief Financial Officer & Treasurer

892,477

1969

Yann Mazabraud

Executive Vice President & Head of International

972,148

1973

Pamela J. Cramer

Chief Human Resources Officer

1974

Sarah Ryan

Vice President of Sales & Marketing

N/A

Jim Flaherty

Senior Vice President & General Counsel

N/A

Elisabeth Cronert-Bendell

Senior Vice President & Head of Strategy

N/A

Christopher German

Corporate Controller & Principal Accounting Officer

1972

David Connolly

Head of Investor Relations & Corporate Communications

N/A

Description

Rhythm Pharmaceuticals, Inc. is a biopharmaceutical company with commercial products, dedicated to the discovery, development, and market launch of therapies addressing rare genetic conditions that cause obesity. Its leading pharmaceutical, IMCIVREE, functions as a powerful agonist of the melanocortin-4 receptor (MC4R). This medication is indicated for treating obesity stemming from deficiencies in pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1 (PCSK1), or the leptin receptor (LEPR), alongside its use in patients with Bardet-Biedl and Alström syndromes. Furthermore, the company is progressing setmelanotide (the active compound in IMCIVREE) through Phase II clinical trials. These studies are evaluating its potential for a broader spectrum of applications, including obesity caused by heterozygous POMC or LEPR deficiencies, steroid receptor coactivator 1 (SRC1) deficiency, SH2B1 deficiency, MC4 receptor deficiency, and obesity associated with Smith-Magenis syndrome, POMC epigenetic disorders, and other MC4R-related conditions. Rhythm Pharmaceuticals holds a collaborative research agreement with the Clinical Registry Investigating Bardet-Biedl Syndrome. The firm, headquartered in Boston, Massachusetts, was established in 2008 and changed its name from Rhythm Metabolic, Inc. to Rhythm Pharmaceuticals, Inc. in October 2015.